Lynch Syndrome: The Most Common Hereditary Cancer Syndrome You Might Not Know About

By Amanda Shrewsbury, MS, CGC

> Key Takeaway: Lynch syndrome is the most common hereditary cancer syndrome, caused by variants in the mismatch repair genes (MLH1, MSH2, MSH6, PMS2, EPCAM). It significantly raises colorectal and endometrial cancer risk — but it''s also one of the most actionable hereditary diagnoses, manageable through enhanced screening, risk-reducing surgery, and daily low-dose aspirin.

When most people hear "hereditary cancer risk," they think of BRCA1 and BRCA2 and breast cancer. But the most common inherited cancer syndrome isn''t related to breast cancer at all. It''s Lynch syndrome, and it primarily raises the risk of colorectal and endometrial cancers, along with several others.

An estimated 1 in 279 people carries a Lynch syndrome variant, which translates to roughly 1 million people in the United States alone (Hampel et al., 2005; MD Anderson Cancer Center, 2024). Yet the vast majority don''t know they have it. Lynch syndrome accounts for about 3–5% of all colorectal cancers and roughly 2.5% of endometrial cancers, but most carriers are never identified because the condition doesn''t produce symptoms until cancer develops.

Whether you''re exploring genetic testing because of a concerning family history, or you''ve already been diagnosed with a Lynch-associated cancer and are learning about the genetic connection, understanding Lynch syndrome is the first step toward taking control of your risk.

What Is Lynch Syndrome?

Lynch syndrome, previously known as hereditary nonpolyposis colorectal cancer (HNPCC), is caused by a pathogenic variant (a disease-causing DNA change) in one of the body''s mismatch repair (MMR) genes. These genes act as your DNA''s spell-check system. Every time a cell divides and copies its DNA, small errors can occur. The MMR genes are responsible for catching and correcting those errors. When one of these genes isn''t working properly, mistakes accumulate, and cells become more likely to grow out of control, which is the beginning of cancer.

There are four MMR genes associated with Lynch syndrome: MLH1, MSH2, MSH6, and PMS2. A fifth gene, EPCAM, can also cause Lynch syndrome when large deletions in EPCAM silence the neighboring MSH2 gene. The specific gene involved matters because each carries different levels of risk for different cancers.

Lynch syndrome follows an autosomal dominant inheritance pattern, meaning each child of a carrier has a 50% chance of inheriting the variant. Both men and women are equally likely to carry and pass on Lynch syndrome. It doesn''t skip generations: if your children don''t carry it, your grandchildren won''t be affected through that line.

What Cancers Does Lynch Syndrome Cause?

Lynch syndrome significantly increases the risk of several types of cancer, with colorectal and endometrial cancers being the most common. The specific risks depend on which MMR gene is involved.

Colorectal cancer is the hallmark risk. In the general population, the lifetime risk of colorectal cancer is about 4–5%. For people with Lynch syndrome, the degree of increased risk depends heavily on which gene is involved. Carriers of MLH1 and MSH2 variants face the highest colorectal cancer risks, with prospective data showing approximately 50% under surveillance and older retrospective studies estimating up to 60–80%. MSH6 carriers face a more moderate CRC risk of approximately 18–20%. PMS2 carriers have the lowest Lynch-associated colorectal cancer risk, with the largest study estimating approximately 12–13% to age 80 (roughly double the general population rate), and no cancers observed before age 50 in prospective data (ten Broeke et al., 2018; Sampson et al., 2020; NCCN, 2025).

Endometrial cancer is the second most common Lynch-associated cancer. Women with MLH1, MSH2, or MSH6 variants face a 28–60% lifetime risk of endometrial cancer, with MSH2 and MSH6 variants conferring the highest risks. PMS2-associated endometrial cancer risk is considerably lower, estimated at approximately 13–14% to age 80 (ten Broeke et al., 2018). For context, the general population risk is about 3%.

Other cancers associated with Lynch syndrome include ovarian (4–11%), stomach (5–8%), urinary tract (up to 8%), small bowel, bile duct, pancreatic, brain (glioblastoma, 1–3%), and certain skin cancers (sebaceous adenomas and carcinomas). The risk for each depends on the specific gene and whether the carrier is male or female.

One thing that makes Lynch syndrome distinct from many other hereditary cancer conditions: cancers tend to develop faster. In the general population, it typically takes about 10 years for a colon polyp to develop into cancer. In people with Lynch syndrome, that process can happen in as little as 30 months. This is why more frequent screening intervals are so important.

How Is Lynch Syndrome Identified?

Lynch syndrome is identified through genetic testing, specifically germline (inherited) testing that looks for pathogenic variants in the MMR genes. There are several pathways to a diagnosis.

Through tumor testing. If someone is diagnosed with colorectal or endometrial cancer, their tumor may be tested for microsatellite instability (MSI) or loss of mismatch repair proteins through immunohistochemistry (IHC). These tumor-level tests don''t diagnose Lynch syndrome directly, but they flag cases that should be followed up with germline genetic testing. Many cancer centers now perform this testing routinely on all colorectal and endometrial tumors, which is how Lynch syndrome is increasingly being caught.

Through a multigene panel. If you''re pursuing genetic testing because of a concerning family history, your genetic counselor may recommend a multigene panel that includes the MMR genes alongside other cancer predisposition genes like BRCA1 and BRCA2. This is the approach used at ClearPath Genetics.

Through cascade testing. If a family member has already been diagnosed with Lynch syndrome, you can be tested for your family''s specific known variant. This is a targeted, typically insurance-covered test with a clear yes-or-no answer. (Learn more about why sharing results with family matters in our guide: How to Talk to Your Family About Genetic Testing.)

A genetic counselor plays a critical role in all of these pathways. They help determine which testing approach is right for your situation, interpret the results, and translate the findings into a personalized plan. (See what this process looks like step by step: What Actually Happens During a Genetic Counseling Appointment.)

What Happens If You Test Positive for Lynch Syndrome?

A positive result means a pathogenic variant was found in one of your MMR genes. It doesn''t mean you will develop cancer. What it does mean is that you have a significantly higher risk than the general population, and that risk can be actively managed through screening, prevention, and in some cases, medication.

If you haven''t been diagnosed with cancer

Your genetic counselor and care team will build a surveillance plan based on your specific gene, your age, your sex, and your family history. NCCN guidelines generally recommend:

Colonoscopy every 1–2 years, starting at age 20–25 for MLH1, MSH2, and EPCAM carriers (or 2–5 years before the earliest family diagnosis if that''s younger). For MSH6 and PMS2 carriers, colonoscopy is recommended starting at age 30–35, repeated every 1–3 years. The wider interval for MSH6/PMS2 reflects their lower colorectal cancer penetrance. This is more frequent than standard screening because Lynch-associated polyps can progress to cancer much faster than average.

Upper endoscopy every 2–4 years, starting at age 30–40, to screen for stomach and small bowel cancers. Earlier or more frequent surveillance may be recommended depending on family history.

Endometrial cancer monitoring. While there is no universally proven screening protocol for endometrial cancer in Lynch syndrome, endometrial biopsy every 1–2 years starting at age 30–35 may be considered. Reporting any abnormal uterine bleeding promptly is important for all women with Lynch syndrome.

Gynecologic risk reduction. Women with Lynch syndrome may consider prophylactic hysterectomy and removal of the ovaries and fallopian tubes (bilateral salpingo-oophorectomy) once childbearing is complete. This significantly reduces the risk of endometrial and ovarian cancers.

Aspirin for cancer prevention. The CAPP2 clinical trial demonstrated that daily aspirin can reduce colorectal cancer risk in people with Lynch syndrome by approximately 50%. The follow-up CAPP3 trial, whose results were presented at the Cancer Research UK Cancer Prevention Research Conference in June 2025, found that a low daily dose (75–100 mg) appears to work as effectively as higher doses, with fewer side effects (Burn et al., 2025). Whether aspirin is right for you depends on your medical history and should be discussed with your care team.

Urine cytology may be recommended to screen for urinary tract cancers, and a baseline dermatology evaluation may also be considered for Lynch-associated skin findings, particularly in MSH2 carriers.

If you''ve been diagnosed with cancer

Your Lynch syndrome diagnosis may influence your treatment plan in important ways. Lynch-associated tumors are characterized by microsatellite instability (MSI-high), which means they accumulate many mutations. This makes them particularly responsive to immune checkpoint inhibitor therapies, which have shown remarkable effectiveness in MSI-high cancers. Your oncologist can factor your Lynch syndrome status into treatment decisions.

Your diagnosis also carries implications for your family. Cascade testing can identify which of your relatives carry the same variant, giving them the opportunity to begin enhanced screening before cancer develops.

How Is Lynch Syndrome Different from BRCA?

Both Lynch syndrome and BRCA are autosomal dominant hereditary cancer syndromes with a 50% chance of being passed to each child. But they involve different genes, different cancers, and different management approaches.

BRCA1 and BRCA2 are involved in DNA double-strand break repair and primarily increase the risk of breast and ovarian cancers, with additional risks for prostate, pancreatic, and other cancers. Lynch syndrome involves the mismatch repair genes and primarily increases the risk of colorectal and endometrial cancers.

Because the cancer types and screening protocols differ substantially, working with a genetic counselor who can walk through the specific implications of your result is essential. For a broader understanding of what different types of results mean, see our guide: What Your Genetic Test Results Actually Mean.

Does Lynch Syndrome Affect Men and Women Equally?

Yes and no. Both men and women are equally likely to inherit Lynch syndrome, and both face increased colorectal cancer risk. But the cancer risks diverge by sex.

Men with MLH1 or MSH2 variants face a higher lifetime risk of colorectal cancer (up to 60–80%) compared to women with the same variants (approximately 40–60%). Men also face increased risks for stomach, urinary tract, and prostate cancers.

Women face the additional and substantial risks of endometrial cancer (28–60%) and ovarian cancer (4–11%), which don''t apply to men. This means that for women with Lynch syndrome, management includes gynecologic surveillance and potentially risk-reducing surgery in addition to the colonoscopy and upper endoscopy schedule.

One important note: because hereditary cancer testing is so strongly associated with breast cancer and BRCA in the public consciousness, male relatives are sometimes less likely to be informed about a family variant or to pursue testing. But Lynch syndrome affects men at least as much as women for colorectal cancer, and possibly more. Sharing results with all family members — including brothers, fathers, sons, uncles, and nephews — matters.

You Have Options

A Lynch syndrome diagnosis can feel overwhelming, especially because it touches so many different cancer types and requires ongoing, lifelong management. But the key takeaway is this: Lynch syndrome is one of the most actionable hereditary cancer diagnoses you can receive. Enhanced screening catches cancers early, when they''re most treatable. Risk-reducing surgery can dramatically lower gynecologic cancer risk. And new evidence shows that something as simple as a daily low-dose aspirin may cut colorectal cancer risk in half.

You don''t have to navigate this alone. A genetic counselor who specializes in hereditary cancer can help you build a plan that fits your specific gene, your risk profile, and your life.

Have a question? Reach out anytime:

Email: hello@clearpathgenetics.com
Text or call: +1 (720) 799-0730

References

Burn, J., Sheth, H., Elliott, F., et al. (2025). Cancer prevention with aspirin in Lynch syndrome (CaPP3): A randomised, double-blind, dose non-inferiority trial. Presented at Cancer Research UK Cancer Prevention Research Conference, London, June 2025. Full peer-reviewed publication pending.
Hampel, H., Frankel, W. L., Martin, E., et al. (2005). Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). New England Journal of Medicine, 352(18), 1851–1860.
National Comprehensive Cancer Network. (2025). Genetic/familial high-risk assessment: Colorectal, endometrial, and gastric (Version 1.2025). https://www.nccn.org
Sampson, J. R., Seppälä, T. T., ten Broeke, S. W., et al. (2020). Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: Findings from the Prospective Lynch Syndrome Database. Genetics in Medicine, 22(1), 15–25.
ten Broeke, S. W., van der Klift, H. M., et al. (2018). Cancer risks for PMS2-associated Lynch syndrome. Journal of Clinical Oncology, 36(29), 2961–2968.